TY - JOUR T1 - Risk of malignancy in patients treated for systemic necrotising vasculitis JF - Annals of the Rheumatic Diseases JO - Ann Rheum Dis SP - 431 LP - 433 DO - 10.1136/annrheumdis-2019-216452 VL - 79 IS - 3 AU - Antoine Lafarge AU - Adrien Joseph AU - Christian Pagnoux AU - Xavier Puechal AU - Pacal Cohen AU - Maxime Samson AU - Mohamed Hamidou AU - Alexandre Karras AU - Matthieu Groh AU - Thomas Quemeneur AU - Camillo Ribi AU - Luc Mouthon AU - Loic Guillevin AU - Benjamin Terrier A2 - , Y1 - 2020/03/01 UR - http://ard.bmj.com/content/79/3/431.abstract N2 - Reduction in cyclophosphamide cumulative dose and introduction of newer immunosuppressive drugs may reduce the malignant burden of systemic necrotising vasculitis (SNV).1 2 This study aimed to describe malignancies recorded in five randomised controlled trials in SNV conducted by the French Vasculitis Study Group and to identify predictive factors.CHUSPAN, CHUSPAN 2, WEGENT, CORTAGE and MAINRITSAN trials evaluated different therapeutic strategies, summarised in online supplementary table S1, for the treatment of newly diagnosed or relapsing SNV. Informations regarding methods and references are provided in the online supplementary materials. The primary endpoint was the occurrence of malignancy.Supplementary data [annrheumdis-2019-216452supp001.pdf] A total of 733 patients included between 1993 and 2012 were pooled. Baseline characteristics of the population are summarised in table 1. During a 4485.9 person-years (PY) observation period, 39 (5.3%) patients developed malignancies (869.5 per 100 000 PY), including solid cancers in 34 (4.6%) cases (757.9 per 100000 PY) and haematological malignancies in 5 … ER -